scholarly journals A potential in situ gel formulation loaded with novel fabricated poly(lactide-co-glycolide) nanoparticles for enhancing and sustaining the ophthalmic delivery of ketoconazole

2017 ◽  
Vol Volume 12 ◽  
pp. 1863-1875 ◽  
Author(s):  
Tarek Ahmed ◽  
Bader Aljaeid
2020 ◽  
Vol 591 ◽  
pp. 120010
Author(s):  
Viliana Gugleva ◽  
Stefka Titeva ◽  
Neli Ermenlieva ◽  
Sonya Tsibranska ◽  
Slavka Tcholakova ◽  
...  

2015 ◽  
Vol 77 (3) ◽  
pp. 654-665 ◽  
Author(s):  
Dipiksha Sawant ◽  
Panchaxari Mallappa Dandagi ◽  
Anand Panchaxari Gadad

2018 ◽  
Vol 29 (42) ◽  
pp. 425101 ◽  
Author(s):  
Yifeng Wen ◽  
Junfeng Ban ◽  
Zhenjie Mo ◽  
Yan Zhang ◽  
Peigang An ◽  
...  

Author(s):  
INSAN SUNAN KURNIAWANSYAH ◽  
TAOFIK RUSDIANA ◽  
IYAN SOPYAN ◽  
ANAS SUBARNAS

Poor bioavailability is one of the most significant problems in the delivery of the ocular drug system. Ophthalmic ointments, solutions and suspensions are the most frequently used dosage forms to treat ocular disease, and their effectiveness as a drug are compromised by several limitations that lead to poor ocular bioavailability. In situ gel is one of the most promising strategy and solutions to improve the ocular bioavailability of drugs. The purpose of this review is to discuss the formulation and characterization of in situ gel. This review is written based on the data or information obtained by using several search engines and several scientific journals, focused on Poloxamer 407 and Hydroxy Propyl Methyl Cellulose (HPMC) bases combination. Active ingredients to treat ocular disease such as Ciprofloxacin, Fluconazole and Ofloxacin can be formulated with the combination of Poloxamer 407 as polymer gelling agent and HPMC as viscosity enhancer to produce good quality in situ gel dosage forms. The in situ gel dosage forms can be a promising alternate solution for the ophthalmic delivery system.


2018 ◽  
Vol 6 (2) ◽  
pp. 36 ◽  
Author(s):  
Shivani Kala ◽  
Prachi Gurudiwan ◽  
Divya Juyal

Author(s):  
Vikas V. Gaikwad ◽  
Abasaheb B. Patil ◽  
Madhuri V. Gaikwad

Scaffolds are used for drug delivery in tissue engineering as this system is a highly porous structure to allow tissue growth.  Although several tissues in the body can regenerate, other tissue such as heart muscles and nerves lack regeneration in adults. However, these can be regenerated by supplying the cells generated using tissue engineering from outside. For instance, in many heart diseases, there is need for heart valve transplantation and unfortunately, within 10 years of initial valve replacement, 50–60% of patients will experience prosthesis associated problems requiring reoperation. This could be avoided by transplantation of heart muscle cells that can regenerate. Delivery of these cells to the respective tissues is not an easy task and this could be done with the help of scaffolds. In situ gel forming scaffolds can also be used for the bone and cartilage regeneration. They can be injected anywhere and can take the shape of a tissue defect, avoiding the need for patient specific scaffold prefabrication and they also have other advantages. Scaffolds are prepared by biodegradable material that result in minimal immune and inflammatory response. Some of the very important issues regarding scaffolds as drug delivery systems is reviewed in this article.


Sign in / Sign up

Export Citation Format

Share Document